ProCE Banner Activity

Decisions Regarding Antiretroviral Drug Therapy in PWH With an Increased Risk of Cardiovascular Disease

Clinical Thought
Get my take on ART modification to reduce CVD risk in PWH, including discussion of the growing evidence associating certain ARVs with increased CVD risk.

Released: November 29, 2021

Expiration: November 28, 2022

Share

Faculty

Jens D. Lundgren

Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark

Jens D. Lundgren, MD, DMSc, has no relevant conflicts of interest to report.